The purpose of this study is to learn about the effects of the study medicine called Paxlovid [nirmatrelvir-ritonavir/PF-07321332], for the potential treatment of COVID-19.
This study will use patient health records in Ontario, to find people who were sick with COVID-19 and visited a pharmacist to be treated, anytime from December 1st, 2022, to March 31st, 2024. To be included in our study, the people must be over 18 years of age and be registered in the Ontario health system for at least one year. People were not included in our study if they have been pregnant in the past year or have serious kidney or liver disease.
We will separate the people in the study into two groups: those who received treatment with Paxlovid [nirmatrelvir-ritonavir/PF-07321332] and those who received no treatment. We will monitor their healthcare visits or if they die for any reason, for up to 60 days after the date that they visited their pharmacist. Then we will compare participant experiences when they are taking the study medicine to when they are not. This will help us determine if the study medicine is effective.

开始日期2025-10-27

申办/合作机构

Pfizer Inc.

NCT07089680

/ Not yet recruitingN/A

Impact of Nirmatrelvir and Ritonavir (PAXLOVID?) on Mortality, Progression to Severe Disease, and Activities of Daily Living (ADL) Worsening in Long-term Care Hospitals (LTCHs) in Korea

The purpose of this study is to learn about the effects of the study medicine (called Paxlovid) for the possible treatment of COVID-19 in older adults who live in long-term care hospitals (LTCHs) in Korea. Researchers want to know whether Paxlovid lowers the chance of severe illness or death and helps people carry out their usual daily activities, remain free from aging and weakness, and maintain cognitive function.
This study is seeking participants who:
* are 60 years of age or older
* live in a long-term care hospital in Korea
* were diagnosed with COVID-19 on or after 14 January 2022, during the period when Paxlovid was available as part of routine care
* received Paxlovid within 5 days after their first COVID-19 symptoms (only for people in the Paxlovid group)
All participants in this study received their usual COVID-19 care. About half also received Paxlovid. Paxlovid was prescribed as part of routine care at the long-term care hospital, typically taken by mouth 2 times a day for 5 days.
The study team will compare the health results of people who received Paxlovid to those who did not, using similar parameters such as age, sex, and medical history. This will help the study team to understand whether Paxlovid makes a meaningful difference in stopping severe illness, death, or slow-down daily functioning.
Participants will not have any extra study visits or tests. The study team will only review information already recorded in their medical charts for up to 1 year after their COVID-19 symptom onset.

开始日期2025-08-18

申办/合作机构

Pfizer Inc.

NCT06397144

/ Withdrawn临床1期

A PHASE 1, OPEN-LABEL, RANDOMIZED, SINGLE DOSE, CROSSOVER STUDY TO DETERMINE THE BE OF NIRMATRELVIR FOLLOWING ORAL ADMINISTRATION OF FDC TABLETS RELATIVE TO THE PAXLOVID® COMMERCIAL TABLETS IN HEALTHY ADULT PARTICIPANTS UNDER FASTED CONDITIONS

Medicines that may have different names or be made in different ways but have the same effect on the body are called bioequivalent.
The purpose of this study is to learn about the bioequivalence of nirmatrelvir plus ritonavir after taking 2 different combination tablet forms by mouth. These combination tablets are compared to the tablet formulation that is already in the market. This study will be done under fasted conditions in healthy adult participants.
This study is seeking participants who are:
* Male and non-pregnant female participants aged 18 years and above.
* with a body weight of more than 50 kilograms and Body Mass Index (BMI) between 16 to 32 kilograms per meter squared.
* are healthy as confirmed by medical history, physical examination, laboratory tests.
The study will also look at the safety and tolerability of nirmatrelvir plus ritonavir combination tablet and marketed tablet formulations in healthy adult participants.
The study will consist of 4 treatments:
Treatment A: Single oral dose of nirmatrelvir plus ritonavir 150 (1 × 150)/100 milligrams marketed tablets under fasted conditions (Reference 1) Treatment B (low dose strength): Single oral dose of nirmatrelvir plus ritonavir 150/100 milligrams (2 × [75/50 milligrams]) combination tablets under fasted conditions (Test 1) Treatment C: Single oral dose of nirmatrelvir/ritonavir 300 (2 × 150)/100 milligrams marketed tablets under fasted conditions (Reference 2) Treatment D (high dose strength): Single oral dose of nirmatrelvir/ritonavir 300/100 milligrams (2 × [150/50 milligrams]) combination tablets under fasted conditions (Test 2)
All treatments will be given under fasted conditions. Fasted condition means the participants would not have had anything to eat before taking the medicines.
Around 28 participants will be enrolled in the study. Healthy participants will be tested to see if they can be in the study within 28 days before receiving the study medicine. Selected participants will be admitted to the clinical research unit (CRU) one day before receiving the study medicine and will remain in the CRU until discharge after completing all the treatment periods.
On Day 1 of each period, participants will be given a single dose of study medicine nirmatrelvir/ritonavir 300/100 mg or 150/100 mg by mouth by chance. Study medicine will be given with approximately 240 milliliters of room temperature water under fasted conditions (overnight fast of at least 10 hours and no food until 4 hours after receiving the study medicine). Blood samples will be collected at different times of the day up to 48 hours after taking the study medicine. Participants will be discharged from the CRU on Day 3 of Period 4, after all the study related procedures have been completed.
A follow-up call will be made to participants around 28 to 35 days from receiving the final dose of the study medicine. The study will look at the experiences of participants receiving the study medicine. This will help to understand if the study medicine is safe and effective.

开始日期2025-08-15

申办/合作机构

Pfizer Inc.

100 项与奈玛特韦/利托那韦相关的临床结果

登录后查看更多信息

100 项与奈玛特韦/利托那韦相关的转化医学

登录后查看更多信息

100 项与奈玛特韦/利托那韦相关的专利（医药）

登录后查看更多信息

463

项与奈玛特韦/利托那韦相关的文献（医药）

2025-12-31·JOURNAL OF MEDICAL ECONOMICS

Comparison of work productivity losses in the United States among employees with COVID-19 at high-risk of severe disease who were untreated or treated with nirmatrelvir/ritonavir

Article

作者: Mokgokong, Ruth ; Cislo, Paul ; Evans, Kristin A. ; Fernandez, Maria M. ; Chaudhary, Mohammad A. ; Drabo, Emmanuel F. ; Sidhu, Gurinder S. ; Brady, Brenna L. ; Ernst, Frank R. ; Cappelleri, Joseph C.

AIM:

Nirmatrelvir-ritonavir (NMV/r; Paxlovid) treatment reduces COVID-19-related morbidity, mortality, and direct healthcare burdens. To investigate the potential impact of NMV/r on indirect disease burdens, we compared workplace productivity between employees diagnosed with COVID-19 who were and were not treated with NMV/r.

METHODS:

Adult employees with COVID-19 at high-risk of severe disease were identified in the Merative MarketScan Health and Productivity Management Database. Index date was the first COVID-19 diagnosis on or after 12/16/2021; employees were followed over a six-month pre-period and ≥30-day post-period. Individuals treated with NMV/r (claim within 5 days of index) were exactly matched 1:1 to untreated employees based on age, sex, index quarter, Charlson Comorbidity Index, and pre-period acute care visits. Lost workdays per-patient-per-month (PPPM) and associated estimated indirect costs due to absence, short-term disability (STD), or long-term disability (LTD) were compared between matched treated and untreated cohorts over the variable post-period using paired t-tests or Chi-squared tests and two-part hurdle models.

RESULTS:

Treated and untreated absence, STD, and LTD analyses included n = 1,909, n = 20,065, and n = 20,318 employees respectively. NMV/r treatment was associated with significantly fewer lost workdays PPPM from absence (mean[SD]: 2.06[2.37] vs. 2.22[2.49], p < 0.05), STD (0.41[2.17] vs. 0.52[2.42], p < 0.001), and LTD (0.02[0.061] vs. 0.04[0.79], p < 0.05) in descriptive analyses. Marginal means from combined two-part hurdle models confirmed treated employees had 5% fewer absence days (mean ratio[95% CI]:0.95[0.91, 0.99]), 17% fewer STD days (mean ratio[95% CI]:0.83[0.77, 0.88]), and 27% fewer LTD days (mean ratio[95% CI]:0.73[0.69, 0.78]) compared to untreated patients (p < 0.01).

LIMITATIONS:

The study sample was derived from large self-insured employers; results may not generalize to small employers or the uninsured and do not reflect other types of productivity loss (e.g. presenteeism).

CONCLUSION:

Within this sample of high-risk employees, NMV/r therapy was associated with reduced societal burdens following COVID-19 infection.

2025-12-22·Journal of Chemical Information and Modeling

Computational Insights into the Regioselective Hydroxylation of Nirmatrelvir Metabolized by Cytochrome P450 3A4

Article

作者: Tang, Yun ; Li, Weihua ; Liu, Guixia ; Tang, Yan ; Fang, Jiaojiao

Nirmatrelvir, a covalent inhibitor of SARS-CoV-2 main protease (M^pro), is the active pharmaceutical ingredient in Paxlovid─the first oral antiviral drug granted emergency use authorization by the U.S. Food and Drug Administration (FDA) for the treatment of COVID-19. Previous studies revealed that the hepatic metabolism of nirmatrelvir was predominantly mediated by cytochrome P450 3A4 (CYP3A4) and that nirmatrelvir can be metabolized to generate multiple products. However, the precise molecular mechanism underlying the regioselective metabolism of nirmatrelvir by CYP3A4 remains to be disclosed. In this study, we performed an integrated computational strategy combining molecular docking, molecular dynamics (MD) simulations, and quantum chemical (QC) calculations to investigate the mechanisms of interaction between CYP3A4 and nirmatrelvir. Our simulation results revealed key insights into the spatial proximity between nirmatrelvir's carbon atoms and the reactive iron(IV)-oxo species (Compound I, Cpd I), with the C23 position showing the greatest accessibility, suggesting a strong preference for this site. Density functional theory (DFT) and quantum mechanics/molecular mechanics (QM/MM) calculations further demonstrated that the transition state for C23 hydroxylation possesses the lowest activation energy barrier, consistent with the experimentally observed regioselectivity in metabolite formation.

2025-12-01·INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Comparative effectiveness of combination therapy with nirmatrelvir-ritonavir and molnupiravir versus monotherapy with molnupiravir or nirmatrelvir-ritonavir in hospitalized COVID-19 patients: A target trial emulation study

Article

作者: Tam, Anthony Raymond ; Choi, Ming Hong ; Wang, Boyuan ; Hung, Ivan Fan Ngai ; Xu, Yahui ; Yuen, Kwok Yung ; Wong, Ian Chi Kei ; Chan, Esther Wai Yin ; Chu, Wing Ming ; Wan, Eric Yuk Fai

BACKGROUND:

Molnupiravir and nirmatrelvir-ritonavir have demonstrated efficacy in reducing hospitalization and mortality among unvaccinated, high-risk COVID-19 outpatients. However, their impact on hospitalized adults remains unclear. Preclinical studies suggest that combining these antivirals may reduce viral shedding and enhance survival.

METHODS:

This target trial emulation study compared the safety and efficacy of combined molnupiravir and nirmatrelvir-ritonavir versus monotherapy in hospitalized COVID-19 patients in Hong Kong. Data from 28,355 patients aged 18 and older, treated within five days of hospital admission between March 16, 2022, and March 31, 2024, were analyzed. Inverse probability of treatment weighting (IPTW) was used to balance baseline characteristics and outcomes, including mortality, ICU admission, and ventilatory support, which were analyzed using Cox proportional hazards models.

RESULTS:

Nirmatrelvir-ritonavir monotherapy significantly reduced mortality risk (HR: 0.62; 95% CI 0.50-0.77; ARR: -3.16%) compared to combination therapy, with no differences in ICU admission or ventilatory support. It also lowered risks of acute liver injury (HR: 0.53 [95% CI 0.32-0.88]), kidney injury (HR: 0.61 [95% CI 0.51-0.74]), and hyperglycaemia (HR: 0.73 [95% CI 0.57-0.93]).

CONCLUSION:

Combining nirmatrelvir-ritonavir and molnupiravir does not significantly reduce mortality, ICU admissions, or ventilatory support needs in hospitalized COVID-19 adults. Nirmatrelvir-ritonavir monotherapy is more effective, but further randomized controlled trials are required to confirm these findings.

FUNDING:

The Health & Medical Research Fund Commissioned Research on COVID-19 (COVID1903010, COVID1903011; COVID19F01).

1,617

项与奈玛特韦/利托那韦相关的新闻（医药）

2025-12-26

·时光组学

利用机器学习从中草药中发现抗新冠病毒的潜力

这篇发表于《Molecules》期刊、由昆明理工大学代绍兴与杨耐雪团队完成的研究，不仅展示了人工智能（AI）在药物筛选中的巨大潜力，也为传统中医药（TCM）在抗击新冠病毒（SARS-CoV-2）中的应用提供了现代科学依据。研究背景：传统智慧与现代科技的交汇自新冠疫情暴发以来，尽管已有多种疫苗和如 Paxlovid 等抗病毒药物问世，但病毒的持续变异和潜在耐药性依然是全球健康的重大挑战。传统中药作为天然产物的重要源泉，其多组分、多靶点的特性在抗疫临床实践中展现了显著疗效，但如何从成千上万的中药成分中快速、高效地锁定核心活性分子，一直是研发的瓶颈。传统的“湿实验”筛选方法耗时耗力且成本高昂，而计算机虚拟筛选，尤其是基于机器学习的预测模型，能够显著提高筛选效率，为开发新型抗病毒药物提供更广阔的化学空间。核心方法：构建AI驱动的“精准指南针” 本研究通过化学信息学与机器学习的深度融合，建立了一套严谨的抗新冠中药成分预测体系。研究团队首先从 ChEMBL 数据库中提取了 105 个活性化合物和 3866 个无活性化合物，并创新性地利用“相似性聚类欠采样”技术解决了数据不平衡问题，构建了高质量的基准数据集。随后，研究者以 FP2 分子指纹作为分子的数字化特征，训练并优化了随机森林（RF）和支持向量机（SVM）模型。为了验证模型的通用性，团队不仅采用了 10 折交叉验证，还利用包含 107 种已知抗新冠药物的独立外部数据集对模型进行了严格“闭卷考试”，确保了预测结果的稳健性。研究结果1. AI预测模型表现出卓越的精确度实验结果显示，RF 和 SVM 两种模型在交叉验证中的平均 AUC 值（衡量模型综合性能的关键指标）均达到了 0.90，显示了极高的识别精度。在外部数据集的测试中，模型准确预测了超过 72% 的活性药物，包括已被 FDA 批准用于临床治疗的 Paxlovid 和莫诺拉韦（Molnupiravir），这有力地证明了该 AI 系统具有强大的泛化能力和实战价值。2. 从本草宝库中锁定 1011 种潜在活性成分通过对 TCMSP 数据库中 6526 种草药衍生化合物的大规模筛选，模型成功识别出 1011 种具有潜在抗新冠活性的化合物。结构分类分析表明，这些成分大多属于黄酮类化合物（共 390 种），该类物质在以往研究中已被证实具有显著的抗病毒和免疫调节作用。更具意义的是，分子指纹相似性分析显示，这些预测出的成分中绝大多数（除 24 种外）与现有 FDA 批准的药物结构相似度较低，这意味着它们可能代表了全新的抗病毒化学骨架。3. 确定 74 种核心药用植物及其靶点机制基于富集分析，研究团队进一步还原出 74 种具有显著抗病毒潜力的药用植物，这些植物广泛分布于 43 个科。其中，18.9% 的植物（如甘草、黄芩等）属于中医理论中的“清热解毒药”，这与临床治疗方案高度契合。分子对接模拟显示，筛选出的活性成分中有 278 个化合物能同时作用于病毒生命周期中的关键蛋白——3CLpro（主蛋白酶）和 RdRp（聚合酶），展示了中药成分“多靶点打击”的独特优势。结果意义：开启中医药研发新范式该研究的成功不仅在于发现了一系列极具潜力的候选药物和植物资源，更在于其展示了“数字本草”的研发新范式。它证明了 AI 技术可以作为传统医学经验的“倍增器”，在极短的时间内从浩如烟海的文献和数据中提炼出核心价值，为中药方剂（如清肺排毒汤）的有效性提供了现代计算生物学的解释依据。这一成果为挖掘中药宝库、开发新型广谱抗病毒药物提供了一个高效且具有前瞻性的切入点，对于应对未来潜在的突变株挑战具有重要的参考价值。注：上述内容和配图由Gemini 3 Pro 以及Nano banana Pro 基于发表论文进行文章解读并生成初稿，经过人工核对形成终稿。

2025-12-25

·今日头条

AI将中国创新药研发周期“砍半”：患者等药时间加速缩短

> 一款创新药从实验室走向患者，传统路径平均需要 10-15年，耗资数十亿美元，且成功率极低。如今，这一漫长而昂贵的进程正被人工智能（AI）技术深刻改变。在《“十四五”生物经济发展规划》等国家战略推动下，以晶泰科技、百济神州为代表的中国企业，正利用AI平台将新药研发效率推向新高度，整体研发周期有望缩短约50%。 1. 传统研发之困：十年磨一剑的代价创新药研发如同“大海捞针”，科学家需要在浩如烟海的化合物中反复试错。传统流程中，靶点发现、分子筛选、临床前研究及临床试验等环节层层递进，耗时漫长。这不仅意味着巨额的资金投入，更让许多急需新药的患者在等待中错过最佳治疗时机。行业数据显示，传统新药研发成功率长期低于10%。 2. AI破局：从靶点到临床的全面加速 AI的介入，通过强大的数据分析和预测能力，正在多个关键环节实现突破，将原本依赖经验和运气的流程转变为数据驱动的高效路径。 - **靶点发现**：AI能快速分析海量基因组、蛋白质组等生物学数据，精准识别潜在药物靶点。百济神州利用AI算法分析此类数据，显著缩短早期药物发现周期。 - **分子设计与优化**：这是AI大显身手的核心。通过生成式AI和计算模拟，可以在虚拟空间中快速设计、筛选出理想候选分子。晶泰科技的AI多肽平台PepiX™，能将多肽药物研发周期缩短至**传统模式的1/3**。其平台平均**1-2个月**即可生成苗头化合物，并将分子与靶蛋白的亲和力优化效率提升**10倍以上**。 - **临床试验优化**：AI可通过分析患者数据，实现更精准的患者分层与招募，预测药物疗效和安全性。有行业报告显示，采用AI技术进行患者招募，能将招募周期缩短**50%**以上。 > 晶泰科技联合创始人温书豪表示：“我们自身也观察到，通过AI，许多研发项目的时间能缩短一半左右。” 3. 案例深潜：晶泰与百济的AI实践中国AI制药企业已从技术探索迈入规模化合作与商业化验证的新阶段。 **晶泰科技PepiX™平台**在2025年12月与代谢疾病龙头**甘李药业**达成全球战略合作。根据协议，甘李药业将依托PepiX™平台，运用AI生成式设计、稳定性提升等全链条“AI+湿实验”能力，完成候选药物的精准设计与高效筛选，旨在**显著缩短研发周期**。此外，晶泰科技孵化的希格生科，利用“类器官+AI”技术，仅用约**半年**时间就找到了传统需要数年的临床前候选化合物（PCC）。 **百济神州**则积极利用AI算法加速早期药物发现。其AI平台在2023年完成了**12个候选药物的筛选**。更重要的是，该公司通过AI平台将候选药物的筛选时间从传统的**5年缩短至18个月**。百济神州通过AI预测小分子与靶点的结合活性，优化候选药物设计，以提高药物的成药性和安全性。 4. 政策东风：国家战略赋能产业跃升国家层面的战略规划为AI制药行业注入了强劲动力。 - **顶层设计**：《“十四五”生物经济发展规划》明确提出推动**人工智能与生物医药深度融合**，支持建设AI驱动的新药创制平台。 - **监管创新**：国家药监局（NMPA）已于2024年启动**AI辅助药物研发审评试点**，探索适应性监管框架。 - **地方扶持**：北京、上海、苏州等生物医药产业集聚区出台专项政策。例如，北京昌平“生命谷”对AI制药等前沿领域项目给予资金支持，**最高研发补贴可达3000万元**。这些政策构建了从基础研究到市场准入的全链条支持体系，降低了企业的研发风险与运营成本，加速了技术商业化落地。 5. 未来图景：更快的药，更多的希望 AI赋能已不再是概念，而是正在发生的产业革命。其影响深远： - **效率与成本**：据晶泰科技数据，其AI平台能将药物发现周期从传统1-2年缩短至数月，研发成本降低**40%-60%**。 - **成功率提升**：AI技术通过早期剔除无效化合物，预测药物代谢与毒性，有望将新药研发成功率提升至20%以上。 - **患者受益**：研发周期的大幅缩短，意味着癌症、糖尿病等重大疾病患者能更快用上创新疗法。例如，辉瑞新冠口服药Paxlovid在晶泰科技AI算法助力下，优势晶型确认工作仅用**6周**，为药物提前上市争取了宝贵时间。随着技术不断成熟与政策持续支持，中国创新药研发正凭借“AI加速度”在全球竞争中寻求换道超车。这不仅是效率的提升，更是对生命机会的争取——当“十年磨一剑”变为“五年可期”，那些在病榻上的等待，终将迎来更多曙光。

临床研究临床结果

2025-12-23

·产业智能官

【趋势洞察】】微软2025十大科技成果全解析：超半数瞄准健康医药，巨头在下怎样一盘棋？

微软2025十大科技成果全解析：超半数瞄准健康医药，巨头在下怎样一盘棋？引言：当科技巨头把“健康”写进未来蓝图 2024年末，微软研究院联合全球顶尖科学家发布的《2025年十大突破性科技成果》引发行业震动——10项成果中7项直接关联健康医药，涵盖AI制药、基因编辑、数字疗法等前沿领域。这份名单不仅揭示了微软未来十年的技术押注，更折射出全球科技产业的共识：生命科学，才是AI时代最值得All in的“硬赛道”。今天，我们深度拆解这十大成果，看懂微软如何用技术重构人类健康边界。一、健康医药篇：7大成果直击“生老病死”痛点微软此次将超70%的科研资源倾斜至健康领域，核心逻辑很清晰：当AI解决了算力与算法瓶颈，“解码生命”便成了下一个技术奇点。1️⃣ 成果一：Med-PaLM 3.0——全球首个“全科医生级”医疗大模型技术突破：基于GPT-5架构训练，整合全球3000万份医学文献、10亿条临床病例，支持多模态输入（文本、影像、基因数据），诊断准确率超95%（超越人类专科医生平均水平）。应用场景：基层医院远程会诊、罕见病初筛、患者自诊咨询。微软已与美国梅奥诊所合作试点，将急诊分诊效率提升40%。行业影响：打破医疗资源地域壁垒，让偏远地区也能享受顶级诊疗建议。2️⃣ 成果二：Project BioForge——AI驱动的“细胞工厂” 技术突破：通过强化学习优化细胞培养条件，可定向诱导干细胞分化为心肌细胞、胰岛β细胞等功能细胞，纯度达99.9%，成本仅为传统方法的1/5。应用场景：再生医学（修复受损器官）、糖尿病细胞疗法、神经退行性疾病研究。案例：与诺华合作开发的“胰岛细胞疗法”，已完成灵长类动物实验，有望2027年进入临床。3️⃣ 成果三：GeneEdit-X——高精度基因编辑工具包技术突破：在CRISPR基础上优化脱靶效应，新增“碱基跳跃编辑”功能（无需切断DNA双链即可修改单个碱基），编辑精度提升100倍，安全性获FDA“突破性疗法”认定。应用场景：单基因遗传病根治（如地中海贫血、囊性纤维化）、癌症基因疗法优化。微软布局：已向全球科研机构开源基础版本，推动普惠医疗。4️⃣ 成果四：Digital Twin Patient——患者“数字孪生”平台技术突破：整合个人基因组、生活习惯、实时生理数据（如可穿戴设备监测的心率、血糖），构建动态虚拟患者模型，可预测疾病进展（如癌症转移路径）并模拟用药效果。应用场景：个性化治疗方案制定、临床试验患者筛选（缩短入组时间30%）。用户价值：患者通过微软Health Vault APP查看自己的“数字孪生”，直观理解病情与治疗逻辑。5️⃣ 成果五：Smart Scalpel 2.0——AI手术机器人技术突破：搭载3D视觉+触觉反馈系统，可识别0.1mm级别的血管与神经，自动规避手术风险；内置“术中实时病理分析”模块，切缘癌细胞检测准确率98%。应用场景：神经外科、肿瘤切除等精细手术。微软与直觉外科（达芬奇机器人母公司）联合研发，计划2026年量产。6️⃣ 成果六：Immuno-AI——癌症疫苗“私人定制”平台技术突破：通过分析患者肿瘤突变谱，AI设计个性化抗原肽，联合mRNA技术72小时内合成疫苗，激活特异性T细胞攻击癌细胞。临床数据：在黑色素瘤患者中，客观缓解率达65%（传统疗法约35%），无严重副作用。微软野心：目标将癌症疫苗成本降至10万美元以内（当前CAR-T疗法超百万美元）。7️⃣ 成果七：NeuroLink Pro——脑机接口“意念操控”升级技术突破：非侵入式头环通过EEG+ fNIRS双信号采集，实现“意念打字”（每分钟60词）、“机械臂精准抓取”，并新增“情绪调节”功能（通过电刺激缓解抑郁）。应用场景：渐冻症患者沟通、瘫痪患者运动功能重建、心理健康干预。伦理考量：微软设立独立伦理委员会，严格限制非医疗用途。二、前沿科技篇：3大成果夯实“健康底座” 剩余3项成果虽不直接属于健康医药，却为上述应用提供了底层支撑，体现微软“技术生态化”布局。8️⃣ Azure Quantum Health——量子计算赋能药物模拟技术亮点：利用量子比特并行计算能力，将蛋白质折叠模拟速度提升1000倍，助力AI制药企业快速筛选候选分子（如新冠口服药Paxlovid的优化版）。9️⃣ HoloLens 3 Medical——AR手术导航系统技术亮点：医生佩戴AR眼镜可叠加患者CT/MRI影像到真实术野，实时显示肿瘤边界与血管位置，误差小于1mm，已在约翰霍普金斯医院完成500例骨科手术。🔟 Eco-Sensor Network——环境健康预警平台技术亮点：通过全球部署的传感器网络监测空气/水质污染物，AI预测传染病传播风险（如流感、登革热），提前14天向公共卫生部门预警。三、微软的“健康野心”：从技术到生态的全面渗透细数这十大成果，微软的战略意图呼之欲出：短期：通过Med-PaLM、Digital Twin Patient等工具抢占医疗入口，积累海量临床数据反哺AI模型；中期：以GeneEdit-X、Immuno-AI等核心技术切入药物研发与疗法创新，与传统药企分成（如与诺华的合作模式）；长期：构建“预防-诊断-治疗-康复”全生命周期健康管理生态，成为医疗体系的“操作系统”。正如微软CEO纳德拉所言：“未来十年，衡量科技公司价值的不是算力，而是能否让人类多活10年、少受10年病痛折磨。”四、对普通人的启示：健康科技不再是“科幻” 微软的十大成果看似遥远，实则已渗透到生活细节：患者：未来看病可能先与Med-PaLM对话，获取初步诊断；从业者：医疗数据分析师、AI临床协调员等新职业需求激增；投资者：关注AI制药（如Insilico Medicine）、数字疗法（如Pear Therapeutics）等赛道。结语当科技巨头把“延长人类健康寿命”作为核心KPI，我们或许正在见证一个时代的转折——从“治疗疾病”到“设计健康”。微软的十大成果不是终点，而是打开“生命科学新纪元”的钥匙。而你，准备好拥抱这个“健康优先”的未来了吗？互动话题如果微软的这些技术落地，你最期待哪一项改善自己的生活？欢迎留言分享！数据来源：微软研究院《2025年十大突破性科技成果白皮书》、Nature Medicine、FDA官网声明：本文基于微软公开技术路线图合理推演，具体成果以官方发布为准。科学智能：在先进产业场景中构建“状态感知-实时认知-自主决策-精准执行-学习提升”的科学智能（Science_and_AI）；实现产业转型升级、DT驱动业务、价值创新创造的产业互联生态链。医药智能：生产疫苗、抗体药物、基因治疗产品等；农业智能：生产生物农药、生物肥料、饲料添加剂和生物育种等；化工智能：生产有机酸、氨基酸、维生素等精细化学品；能源智能：生产生物燃料、生物柴油等；材料智能：生产生物塑料、生物纤维、生物橡胶等。先进产业+物理AI=科学智能产业智能官：Science_and_AI 加入知识星球“产业智能研究院”：产业OT技术（自动化+机器人+工艺+精益）和新一代IT技术（云计算+物联网+区块链+大数据+人工智能）深度融合，在场景中构建“状态感知-实时认知-自主决策-精准执行-学习提升”的科学智能（Science_and_AI）；实现产业转型升级、DT驱动业务、价值创新创造的产业互联生态链。科学智能（Science_and_AI）作为第四次工业革命的核心驱动力，将进一步释放历次科技革命和产业变革积蓄的巨大能量，并创造新的强大引擎；重构设计、生产、供应链和服务等经济活动各环节，形成从宏观到微观各领域的智能化新需求，催生新技术、新产品、新产业、新业态和新模式；引发经济结构重大变革，深刻改变人类生产生活方式和思维模式，实现社会生产力的整体跃升。产业智能化技术分支用来的今天，从业者必须了解如何将科学智能（Science_and_AI）全面渗入整个公司、产品、业务等商业场景中，利用科学智能（Science_and_AI）形成数字化、网络化和智能化力量，实现行业的重新布局、企业的重新构建和焕然新生。版权声明：产业智能官（ID：Science_and_AI）发表的文章，除非确实无法确认，我们都会注明作者和来源，涉权请联系协商解决，联系、投稿邮箱：wolongzy@qq.com

突破性疗法基因疗法

100 项与奈玛特韦/利托那韦相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
新型冠状病毒感染	韩国	Pfizer Inc.	2021-12-27

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
新冠肺炎后遗症	临床2期	瑞典	Pfizer Inc.	2023-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05595369 (RECOVER-VITAL, CTgov)	临床2期	新冠肺炎后遗症	963	Experimental: Paxlovid 25 day dosing (Experimental: Paxlovid 25 Day Dosing)	範獵廠獵餘選繭構蓋顧 = 夢鹽積願鑰顧繭獵鹹鹹夢鏇鹹簾選遞淵遞築簾 (積憲憲壓積廠淵鹹壓顧, 構選蓋衊製積鹽蓋獵鏇 ~ 鏇壓築製艱觸選鑰襯夢) 更多	-	2025-12-02
				Experimental: Paxlovid 15 day dosing (Experimental: Paxlovid 15 Day Dosing)	範獵廠獵餘選繭構蓋顧 = 積憲衊願淵願蓋鬱醖蓋夢鏇鹹簾選遞淵遞築簾 (積憲憲壓積廠淵鹹壓顧, 製簾鏇積獵淵製築鏇淵 ~ 壓獵製簾鑰鹽鑰顧築艱) 更多
GlobeNewswire 人工标引	N/A	新冠肺炎后遗症	27	Valacyclovir + Celecoxib + Pulsed Paxlovid	蓋淵夢齋範願餘衊齋蓋(積衊鏇選衊選窪簾鹽淵): P-Value = <0.0001 更多	积极	2025-09-04
				Valacyclovir + Celecoxib
NCT04960202 (phase 3 randomized trial, Pubmed \| Clin Infect Dis)	临床2/3期	新型冠状病毒感染	2,113	Nirmatrelvir/Ritonavir (NMV/R) 300 mg/100 mg	鏇糧積膚艱鹽鑰窪構鑰(願鹽遞窪鏇範餘製淵鏇) = 築醖遞築糧遞壓獵築遞製積壓顧廠襯觸艱糧構 (簾鏇鹹淵鏇窪餘願鑰選 ) 更多	积极	2024-11-11
				Placebo	鏇糧積膚艱鹽鑰窪構鑰(願鹽遞窪鏇範餘製淵鏇) = 構網製鏇憲願鏇淵齋艱製積壓顧廠襯觸艱糧構 (簾鏇鹹淵鏇窪餘願鑰選 ) 更多
NCT05898672 (CTgov)	临床1期	新型冠状病毒感染	12	Rosuvastatin (Period 1: Rosuvastatin 10 mg)	鹽膚鏇繭餘獵窪獵壓積(鏇夢獵醖鏇鹹窪繭憲願) = 鬱選鑰糧簾膚鏇製積糧糧網齋繭觸構窪觸獵獵 (淵窪鏇淵築鏇簾觸製遞, 46) 更多	-	2024-10-28
				Rosuvastatin+Nirmatrelvir+Ritonavir (Period 2: Rosuvastatin 10 mg + Nirmatrelvir 300 mg/ Ritonavir 100 mg)	鹽膚鏇繭餘獵窪獵壓積(鏇夢獵醖鏇鹹窪繭憲願) = 網壓願餘選鑰齋構夢鹽糧網齋繭觸構窪觸獵獵 (淵窪鏇淵築鏇簾觸製遞, 48) 更多
NCT05339334 (CTgov)	临床1期	-	14	PF-07321332+Ritonavir	遞繭鹹醖顧鏇廠餘襯衊(積膚蓋繭製鹽膚鬱壓築) = 壓鏇鑰淵範製鹽窪積醖蓋蓋鑰網窪構衊積艱繭 (餘構鹽鬱醖鑰範鑰淵廠, 29) 更多	-	2024-10-08
NCT05525910 (CTgov)	临床1期	-	15	Nirmatrelvir+Ritonavir (Nirmatrelvir/Ritonavir 300(2*150)/100 mg)	窪構範衊膚簾淵餘繭鹹(憲齋鹽築鹽艱遞構獵憲) = 廠糧遞醖憲齋鏇構製鬱淵艱鹹獵獵構鏇獵鑰艱 (鏇觸鹹鹹艱醖廠簾選窪, 36) 更多	-	2024-09-19
				Nirmatrelvir+Ritonavir (Nirmatrelvir/Ritonavir 2*(150/50 mg) Low Disintegrant)	窪構範衊膚簾淵餘繭鹹(憲齋鹽築鹽艱遞構獵憲) = 鑰壓鹹構鏇積醖壓衊壓淵艱鹹獵獵構鏇獵鑰艱 (鏇觸鹹鹹艱醖廠簾選窪, 28) 更多
NCT05263921 (CTgov)	临床1期	-	12	Nirmatrelvir+Ritonavir (Nirmatrelvir/Ritonavir 300/100 mg Commercial Tablets)	夢簾觸獵壓製餘齋襯構(憲範衊廠鑰窪製窪衊壓) = 觸構衊鏇夢齋鑰範餘糧夢夢夢簾構築淵壓齋醖 (鏇構鏇窪淵艱壓壓鑰遞, 36) 更多	-	2024-06-06
				Nirmatrelvir+Ritonavir (Nirmatrelvir/Ritonavir 300/100 mg Oral Powder Mixed With Water)	夢簾觸獵壓製餘齋襯構(憲範衊廠鑰窪製窪衊壓) = 齋窪網醖網糧選鑰選衊夢夢夢簾構築淵壓齋醖 (鏇構鏇窪淵艱壓壓鑰遞, 25) 更多
ASCO2024 人工标引	N/A	新型冠状病毒感染	182	Nirmatrelvir/ritonavir	餘選餘餘鹹顧積鹽夢願(鹹願繭構糧鬱願憲構衊) = 醖膚醖積觸窪製壓鹽簾餘選顧餘築構廠繭糧衊 (顧醖網鬱築繭網艱選醖 ) 更多	积极	2024-05-24
NCT05544786 (CTgov)	临床1期	-	12	Nirmatrelvir+Ritonavir (Nirmatrelvir/Ritonavir 300/100 mg Tablets (Fasted))	觸築蓋觸構膚鏇獵獵鹽(選製顧簾憲壓壓鑰衊鏇) = 遞簾鹽網範糧窪製網觸簾餘醖構餘鑰壓淵齋廠 (網廠襯範獵廠觸築簾鏇, 18) 更多	-	2024-05-10
				Nirmatrelvir+Ritonavir (Nirmatrelvir/Ritonavir 300/100 mg Oral Powder Mixed With Water (Fasted))	觸築蓋觸構膚鏇獵獵鹽(選製顧簾憲壓壓鑰衊鏇) = 糧艱簾夢艱廠膚糧夢願簾餘醖構餘鑰壓淵齋廠 (網廠襯範獵廠觸築簾鏇, 22) 更多
NCT05064800 (CTgov)	临床1期	-	24	Dabigatran (Treatment 1: Dabigatran 75 mg)	窪鏇齋網壓鏇構顧獵糧(鹽獵淵鹽構齋襯遞憲壓) = 壓鹽築構淵夢憲鑰憲願觸願夢壓壓鏇淵願築餘 (獵觸繭製願齋願範鹹遞, 78) 更多	-	2024-03-29
				PF-07321332+Dabigatran+Ritonavir (Treatment 2: PF-07321332 300 mg + Ritonavir 100 mg + Dabigatran 75 mg)	窪鏇齋網壓鏇構顧獵糧(鹽獵淵鹽構齋襯遞憲壓) = 鑰廠餘膚簾選簾齋網範觸願夢壓壓鏇淵願築餘 (獵觸繭製願齋願範鹹遞, 72) 更多